Cancer cells may soon lose one of their most effective defenses. Scientists have identified a protein that helps tumors build a protective layer of sugar-derived molecules, shielding them from the immune system. Blocking this protein could make cancer cells more visible to immune attacks, offering a new way to improve treatments.
The protein behind cancer’s invisibility cloak
A recent study in Science Advances focuses on heat shock factor 1 (HSF1). Under high-glucose conditions common in tumors, this protein becomes essential for constructing the glycocalyx, a sugary coating that hides cancer cells from immune surveillance.
“Our findings indicate that changes in mitochondrial function lead to the synthesis of cell surface sugar-derived molecules that make it difficult for the immune system to recognize and kill cancer cells,” said Kevin Tharp, assistant professor at the Sanford Burnham Prebys NCI-Designated Cancer Center. “Now that we know this, it opens a significant opportunity for drug discovery.”
Tharp and his colleagues had previously demonstrated that the stiff, scar-like tissue around tumors doesn’t just block immune cells physically. It also alters the metabolism of cancer and nearby immune cells, creating an environment that weakens immune responses.
How stiffness and sugar fuel tumor growth
Primary tumors are often stiffer than surrounding tissue, a difference that changes how cells process nutrients. The study revealed that both stiffness and glucose levels influence the thickness of the glycocalyx, with glucose having the greater impact.
“We observed that changing the available metabolites for those tumor cells reveals distinct biology for normal and tumor cell metabolism,” Tharp explained. “There was a clear difference between the glycoconjugates of cells cultured in conventional medium versus those grown in a medium that better reflects the nutrient composition of the human body.”
Related: Study Shows Ferroptosis Vulnerability in AML
In experiments simulating high blood sugar, a condition tied to type 2 diabetes, HSF1 levels rose. Cancer cells only increased their immune-evasion tactics when HSF1 was active, showing the protein links high blood sugar to tumor protection.
This relationship may explain why metabolic disorders like diabetes are linked to worse cancer outcomes. If HSF1 is the key, drugs targeting it might remove the glycocalyx, exposing tumors to immune attacks. Such an approach could be particularly useful for metastatic disease, where current immunotherapies often fail.
The concept has practical potential. Tharp’s group sees a direct path to developing HSF1 inhibitors, though clinical use remains years away. The findings provide insight into how tumors exploit metabolic conditions—and how that advantage could be reversed.
“We’ve uncovered a plausible mechanism by which hyperglycemia directly contributes to immune evasion,” Tharp said. “It may also offer a way to counter the pro-tumor effects of hyperglycemia caused by metabolic syndrome and modern diets.”
For now, the research presents a new angle in combating cancer’s adaptability. Success could turn one of the disease’s greatest strengths—its ability to hide—into a vulnerability.
Leave a Reply